Survival outcomes and prognostic predictors after adrenalectomy for renal cell carcinoma adrenal metastasis
Authors:
Open Access
- 28 November 2025
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1)
Abstract
Purpose To evaluate survival outcomes after adrenalectomy for renal cell carcinoma (RCC) adrenal metastasis and to identify risk factors influencing overall survival. Methods We retrospectively reviewed all histologically confirmed cases of RCC adrenal metastasis managed at a tertiary center from January 2013 to December 2024. Overall survival (OS) was estimated with Kaplan–Meier analysis and compared with log-rank tests. Prognostic factors were examined using univariable and multivariable Cox proportional hazards models. Results A total of 82 patients with RCC adrenal metastasis were included (median age 60.5 years; IQR 54.8–67.0). Metachronous disease was present in 52 patients (63.4%), and 8 (9.8%) had bilateral adrenal involvement. Seventy-one patients (86.6%) underwent adrenalectomy; seven with bilateral primary renal tumors were excluded owing to indeterminate timing and/or laterality, leaving 64 for survival analysis. After a median follow-up of 32.5 months (IQR 14.8–80.8), the 1-, 3-, and 5-year OS rates were 96.6% (95% CI 92.2–100.0%), 87.1% (95% CI 77.8–97.6%), and 74.4% (95% CI 61.4–90.2%), respectively. Log-rank analysis showed poorer OS for synchronous presentation (P = 0.02), RCC T3/4 stage (P < 0.001), and primary tumor diameter > 6 cm (P = 0.001). In multivariable Cox analysis, increasing primary tumor diameter was the only independent predictor of reduced OS (HR 1.33, 95% CI 1.02–1.75; P = 0.04). Conclusions Adrenalectomy provides durable survival for well-selected patients with isolated or oligometastatic RCC adrenal metastasis. Prospective multicenter trials comparing surgery with non-surgical modalities are needed to refine management algorithms.Keywords
Funding Information
- Beijing Research Ward Excellent Program (No. BRWEP2024W054070104)
- National High Level Hospital Clinical Research Funding (No.2024IR32)
This publication has 33 references indexed in Scilit:
- The percentage abundance of sarcomatoid component has a prognostic role in grade 4 non-metastatic clear cell-renal carcinomaWorld Journal of Urology, 2025
- Long-term survival following adrenalectomy for secondary adrenal tumors: A systematic review and meta-analysisThe American Journal of Surgery, 2024
- Laparoscopic adrenalectomy for adrenal metastases of solid tumorsSurgical Endoscopy, 2023
- Two nomograms based on radiomics models using triphasic CT for differentiation of adrenal lipid-poor benign lesions and metastases in a cancer population: an exploratory studyEuropean Radiology, 2022
- American Association of Endocrine Surgeons Guidelines for AdrenalectomyJAMA Surgery, 2022
- Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With SurvivalJAMA Network Open, 2021
- Prognostic factors after adrenalectomy for adrenal metastasisInternational Urology and Nephrology, 2020
- Adrenalectomy for metastasis: long-term results and predictors of survivalEndocrine, 2015
- Adrenal Metastectomy is Safe in Selected PatientsWorld Journal of Surgery, 2014
- Adrenalectomy Improves Outcomes of Selected Patients with Metastatic CarcinomaWorld Journal of Surgery, 2012